Anika Therapeutics Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Anika Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANIK, but not buy additional shares or sell existing shares.
View analyst ratings for Anika Therapeutics or view top-rated stocks.

3 brokerages have issued 12-month price objectives for Anika Therapeutics' shares. Their ANIK stock forecasts range from $35.00 to $48.00. On average, they anticipate Anika Therapeutics' stock price to reach $43.00 in the next year. This suggests a possible upside of 91.0% from the stock's current price.
View analysts' price targets for Anika Therapeutics or view top-rated stocks among Wall Street analysts.

Anika Therapeutics' stock was trading at $35.83 at the start of the year. Since then, ANIK stock has decreased by 37.2% and is now trading at $22.51.
View the best growth stocks for 2022 here.

Anika Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Anika Therapeutics.

Anika Therapeutics, Inc. (NASDAQ:ANIK) posted its earnings results on Thursday, May, 5th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.13. The biotechnology company earned $36.69 million during the quarter, compared to analysts' expectations of $33.90 million. Anika Therapeutics had a negative trailing twelve-month return on equity of 0.92% and a negative net margin of 1.09%. During the same quarter in the prior year, the business posted $0.06 earnings per share.
View Anika Therapeutics' earnings history.

Some companies that are related to Anika Therapeutics include West Pharmaceutical Services (WST), Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), QuidelOrtho (QDEL), ICU Medical (ICUI), STAAR Surgical (STAA), Haemonetics (HAE), Merit Medical Systems (MMSI), Neogen (NEOG), Meridian Bioscience (VIVO), Atrion (ATRI), Antares Pharma (ATRS), Cerus (CERS) and Utah Medical Products (UTMD).
View all of ANIK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANIK stock can currently be purchased for approximately $22.51.

Anika Therapeutics (NASDAQ:ANIK) has a market capitalization of $327.39 million and generates $147.79 million in revenue each year. The biotechnology company earns $4.13 million in net income (profit) each year or ($0.110010) on an earnings per share basis.

Anika Therapeutics employs 297 workers across the globe.

Anika Therapeutics was founded in 1992.

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for Anika Therapeutics is www.anikatherapeutics.com. The biotechnology company can be reached via phone at (781) 457-9000, via email at [email protected], or via fax at 781-305-9720.